[Skip to Navigation]
Sign In
In This Issue of JAMA Neurology
September 2013


JAMA Neurol. 2013;70(9):1089-1091. doi:10.1001/jamaneurol.2013.2882


Walczak and colleagues assess the safety and efficacy of transdermally applied myelin peptides in patients with relapsing-remitting multiple sclerosis.

Related Editorial

Kim and coauthors report the results of rituximab treatment in patients with relapsing neuromyelitis optica or neuromyelitis optica spectrum disorder for a median of 60 months.

Related Editorial

Matiello and colleagues evaluate tissue-specific messenger RNA and protein expression and supramolecular aggregation of aquaporin 4 (AQP4) in mouse, rat, and human tissues in an effort to understand the predilection for optic nerve and spinal cord pathologic changes in neuromyelitis optica (NMO).

Prabhakaran and colleagues evaluate the impact that a citywide policy recommending prehospital triage of patients with suspected stroke to the nearest primary stroke center had on intravenous tissue plasminogen activator use in Chicago, Illinois.

Continuing Medical Education

Kayser and coauthors determine the frequency, symptoms, and outcome of isolated psychiatric episodes in a cohort of patients with anti–N-methyl-d-aspartate (NMDAR) encephalitis.

Continuing Medical Education

Chang and colleagues investigate the characteristics and potential pathogenicity of glutamic acid decarboxylase autoantibodies in patients with stiff person syndrome and related disorders.

Shulman and colleagues investigate whether Alzheimer disease susceptibility loci from genome-wide association studies affect neuritic plaque pathology and additionally aim to identify novel risk loci for this trait.

Vossel and coauthors describe common clinical characteristics and treatment outcomes of patients with amnestic mild cognitive impairment or early Alzheimer disease who also have epilepsy or subclinical epileptiform activity.

Thambisetty and colleagues investigate the association between glucose intolerance and insulin resistance and in vivo brain β-amyloid burden, measured with carbon 11–labeled Pittsburgh Compound B and pathological features of Alzheimer disease at autopsy.

Clinical Review & Education

Using 15 years’ experience with parkin-associated Parkinson disease, Grünewald and colleagues evaluate type, quality, and quantity of genetic and phenotypic data and elucidate clinical or genetic features impacting genetic testing and counseling.